FlowOx™ by Otivio

Otivio is a small medtech development company based in Oslo, Norway. Our vision is to stimulate active self care and treatment through simple and easy to use home treatment devices and services.

BIOGRAPHY

FlowOx™ by Otivio is a new direction in self healthcare

Otivio AS is a privately owned company based in Oslo, Norway. The company was founded in 2010 based on IP, prototypes and clinical data developed at University of Oslo. Otivio is ISO 13485 certified. Our main product FlowOx™ is a non-invasive medical device for home use addressing insufficient blood flow to the limbs associated with peripheral arterial disease, diabetes and other medical conditions. These conditions lead to pain, chronic wounds and amputations.

FlowOx™ is documented to reduce or eliminate these outcomes which have a big impact on Quality of Life and health care costs. FlowOx™ represents a solution for transition from hospital to home treatment accentuated by the COVID-19 outbreak. FlowOx™ is CE marked and available in multiple countries including Germany, UK, Norway, Sweden and Denmark.

EMPLOYEES

Who are we at Otivio?

The management team of Otivio has, on average, more than 20 years of experience in the life science industry.

Andreas Mollatt

CEO

+47 934 46 261
am@otivio.com

Brian Alberts

Project and Logistic Coordinator

+47 (0) 930 05 210
ba@otivio.com

Lynsey Adderley-Dey

Business Development Manager UK

+44 (0) 7311 821 833
lad@otivio.com

Iacob Mathiesen

CSO

+47 468 90 416
im@otivio.com

Punit Patel

Head of QA/RA

​​+47 (0) 930 14 786
pp@otivio.com

Tarwinder Singh

Office Administrator

+47 (0) 465 26 169
ts@otivio.com

Michael Taube

General Manager
Otivio GmbH

+49 171 5523182
mt@otivio.com

Henrik Hoel

Clinical Researcher

​​hh@otivio.com

Hans Petter Tjeldflaat

CFO

​​hpt@otivio.com

Claus Kjærsgaaard

CCO

​​+45 538 49 718
​​ck@otivio.com

Jody McIntosh

Clinical Researcher

​​jm@otivio.com


ABOUT FLOWOX™

FlowOx™ in the Press

Otivio has developed FlowOx™ for patients suffering from the effects of PAD such as leg pain and chronic wounds. Early long-term testing documents increased blood flow.

First RCT to show improved walking capacity

First multi-centre randomized controlled trial using FlowOx™, published in Journal of Vascular Surgery, shows improved walking capacity for patients with intermittent claudication, also known as …

COOPERATIVE PARTNERS

With a little help

Otivio has a strong setup of partners and suppliers all the way from design, development and manufacturing to clinical documentation, sales and distribution.

Norway Health Tech

Oslo, Norway

Norway Health Tech is a health technology cluster, dedicated to accelerating and supporting the development of new medtech, eHealth products, services and innovative solutions for the Norwegian and global health care market.

Innokas Medical

Kempele, Finland

Innokas Medical have been producing health technology since 1994. They focus on design and manufacturing of medical equipment under the world’s leading brand names in accordance with their specific strategy and values.

Oslo University Hospital

Aker, Norway

The heart, lung and vascular clinic at Oslo University hospital is Scandinavia’s largest center for cardiovascular disease treatment.

H&R Healthcare

Melton, United Kingdom

Established near Hull in 2006, they represent world-class companies in the product areas of Advanced Wound Management, Compression, Infection Control and Skin Protection.

mediq Innovation Experts GmbH

Frankfurt, Germany

mediq is a strategy and innovation consulting firm for the German and European healthcare market. We specialize in strategy development for technology and service innovations.

Cubist

Alten
St. Olav Hospital
Sørlandet sykehus
DMedical
DNV GL

NEWS

What’s new with FlowOx™?

We are always working on making FlowOx™ the greatest way to treat peripheral artery disease (PAD). Here are our latest news regarding Otivio and FlowOx™.

First RCT to show improved walking capacity

First multi-centre randomized controlled trial using FlowOx™, published in Journal of Vascular Surgery, shows improved walking capacity for patients with intermittent claudication, also known as …
Scroll to Top